Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PRX-012 by Prothena Corp for Alzheimer's Disease: Likelihood of Approval
PRX-012 is under clinical development by Prothena Corp and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...
Data Insights
Risk adjusted net present value: What is the current valuation of Prothena Corp's PRX-012?
PRX-012 is a monoclonal antibody commercialized by Prothena Corp, with a leading Phase I program in Alzheimer's Disease. According to...